Oruka Therapeutics's 15min chart sees MACD Death Cross, KDJ Death Cross

Oruka Therapeutics's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross at 10:00 AM on October 10, 2025. This indicates that the stock price has the potential to continue declining, with a shift in momentum towards the downside and a potential further decrease in value.

Oruka Therapeutics Inc. (ORKA) has faced a significant development in its stock performance, with the 15-minute chart indicating a MACD Death Cross and a KDJ Death Cross at 10:00 AM on October 10, 2025. These technical indicators suggest a potential continuation of the stock's decline and a shift in momentum towards the downside. This move comes amidst the company's ongoing efforts to secure a $500 million mixed shelf offering through the Securities and Exchange Commission (SEC) Oruka Therapeutics Files For Mixed Shelf Of Upto $500 Million - SEC Filing^[1].

The MACD (Moving Average Convergence Divergence) and KDJ (K Moving Average and D Moving Average) indicators are widely used tools in technical analysis. A MACD Death Cross occurs when the MACD line crosses below the signal line, signaling a potential bearish trend. Similarly, a KDJ Death Cross indicates a decline in the K-line below the D-line, suggesting a potential reversal in the stock's momentum. These signals are often interpreted as early warning signs of a potential downturn in stock prices.

In recent developments, Oruka Therapeutics has filed to sell 39,425,806 shares of common stock for holders. This move, as reported by Seeking Alpha, is part of the company's ongoing efforts to raise capital and expand its operations Oruka Therapeutics files to sell 39.43M shares of common stock for holders^[2]. The company's lead drug has shown promising results in early-stage trials, outperforming AbbVie’s Skyrizi, which has been a positive development for the company Oruka Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ORKA | Benzinga^[3].

Despite these positive developments, the recent technical indicators suggest that investors should be cautious. The stock's current price stands at $19.63, with a consensus price target of $42.50, as per Benzinga's data Oruka Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ORKA | Benzinga^[3]. The company's earnings per share (EPS) is $-0.46, which is worse than the industry average, indicating a need for improvement in profitability.

Investors should closely monitor Oruka Therapeutics' performance in the coming weeks and months, as the company prepares to report its Q3 earnings on Wednesday, November 12, 2025. The upcoming earnings report will provide further insights into the company's financial health and operational performance.